Zevra Therapeutics

229 articles about Zevra Therapeutics

• Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company

  11/20/2023

  Zevra Therapeutics, Inc. today announced the completion of its acquisition of Acer Therapeutics Inc.

• Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results

  11/7/2023

  Zevra Therapeutics, Inc., a rare disease therapeutics company, provided corporate updates and reported its financial results for the quarter ended September 30, 2023.

• Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET

  10/31/2023

  Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a conference call and live audio webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET, to review its corporate and financial results for the third quarter of 2023.

• Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout October

  10/19/2023

  Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), a rare disease therapeutics company, proudly supports the Niemann-Pick community on Global Niemann-Pick Disease Awareness Day and throughout Niemann-Pick Disease Awareness Month.

• Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director

  10/10/2023

  Zevra Therapeutics, Inc. today announced that Neil F. McFarlane has been named President and Chief Executive Officer of Zevra and appointed to the Board of Directors, effective October 10, 2023.

• Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting

  10/5/2023

  Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that it will present data related to clinical study outcomes and its early access programs via both oral and poster presentations at the upcoming 52 nd Child Neurology Society (CNS) Annual Meeting.

• Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

  10/2/2023

  Zevra Therapeutics, Inc. announced interim data from the open-label dose titration phase of the Phase 2 clinical trial evaluating KP1077 in patients with idiopathic hypersomnia (IH).

• Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference

  9/20/2023

  Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that executive management will participate in a fireside chat at the Cantor Global Healthcare Conference on Wednesday, September 27, 2023, at 3:00 p.m. ET.

• Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023

  9/10/2023

  Zevra Therapeutics, Inc., a rare disease therapeutics company, announced a poster presentation featuring study data that underscores the cardiovascular safety profile of serdexmethylphenidate, the sole active pharmaceutical ingredient in KP1077, Zevra’s investigational candidate for the treatment for idiopathic hypersomnia, at the Psych Congress 2023 taking place September 6-10, 2023, in Nashville, Tennessee.

• Zevra Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

  9/5/2023

  Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that executive management will present at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13, 2023, at 8:30 a.m. ET.

• Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product

  8/31/2023

  Zevra Therapeutics, Inc. and Acer Therapeutics Inc. announced the companies have entered into a definitive agreement pursuant to which Zevra would acquire Acer in a merger transaction having a total potential value for Acer stockholders of up to $91 million.

• Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results

  8/14/2023

  Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the quarter ended June 30, 2023. 

• Zevra Therapeutics Appoints Thomas Anderson to Board of Directors and Announces Retirement of Matthew R. Plooster

  8/7/2023

  Zevra Therapeutics, a rare disease company melding science, data, and patient need to create transformational therapies for diseases with limited or no treatment options, proudly welcomes Tom Anderson, a highly accomplished biopharma veteran, to its Board of Directors.

• Zevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023

  8/2/2023

  Zevra Therapeutics, Inc. has announced that it will host a conference call and live audio webcast on Monday, August 14, 2023, at 8:30 a.m. ET, to review its corporate and financial results for the second quarter of 2023.

• Zevra Therapeutics to Participate in the 2023 NNPDF Family Support and Medical Conference

  7/19/2023

  Zevra Therapeutics, Inc. today announced their support of the upcoming National Niemann-Pick Disease Foundation’s (NNPDF) Family Support and Medical Conference.

• Zevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023

  6/20/2023

  Zevra Therapeutics, Inc. announced its expected addition to the broad-market Russell 3000 ® Index and small-cap Russell 2000 ® Index in accordance with the 2023 Russell indexes annual reconstitution.

• Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest

  6/13/2023

  Zevra Therapeutics, Inc., a rare disease therapeutics company, announced executive management will participate in the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, Tuesday, June 20 through Thursday, June 22, 2023.

• Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023

  6/3/2023

  Zevra Therapeutics, Inc. will be presented at the Hypersomnia Foundation’s 2023 Beyond Sleepy Conference being held June 2 - 4, 2023, in Indianapolis, IN, for people living with IH, narcolepsy and Kleine-Levin syndrome and their supporters.

• Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results

  5/15/2023

  Zevra Therapeutics, Inc., a rare disease therapeutics company, provided corporate updates and reported its financial results for the quarter ended March 31, 2023.

• Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023

  5/10/2023

  Zevra Therapeutics, Inc. today announced that R. LaDuane Clifton, the Company’s Chief Financial Officer, will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023, at 3:05 p.m. ET.